Lung cancer is a deadly disease that is difficult to diagnose and even m ore difficult to treat effectively. M any pathways are known to affect tum or growth, and targeting these pathways provides the cornerstone by which cancer is treated. Som atostatin receptors (SSTR) are a fam ily of G protein coupled receptors that signal to alter horm onal secretion, increase apoptosis, and decrease cellular proliferation. These receptors are expressed in many normal and m alignant cells, including both sm all cell and non-sm all cell lung cancer. Synthetic analogs of SSTRs are com m ercially available, but their effects in lung cancer are still largely uncertain. Signaling pathway studies have shown that SSTRs signal through phosphotyrosine phosphatases to induce apoptosis as well as to decrease cell proliferation. Radiolabeled SSTR2 analogs are utilized for radiographic im aging of tum ors, which, when com bined with positron em ission tom ography-com puted tom ography (PET-CT) m ay improve detection of lung cancer. These radiolabeled SSTR2 analogs also hold prom ise for targeted chem otherapy as well as radiotherapy. In this review, we sum m arize what is known about SSTRs and focus our discussion on the knowledge as it relates to lung cancer biology, as well as discuss current and future uses of these receptors for im aging and therapy of lung cancer. 
INTRODUCTION
Lung cancer is the leading cause of cancer-related death in the United States (1) . It remains extremely challenging to diagnose in its early stages, and treatment is similarly difficult.
Recent work has shown that new small molecular inhibitors targeted at specific mutated receptors, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), improves outcomes for those selected patient populations (2) .
In this age of emphasis on genotyping tumors for personalized, more targeted therapies, evaluating the role of previously known receptors and proteins could assist in improving treatment and predicting outcomes. In this review, we will describe the different somatostatin receptor subtypes and the role they play in lung cancer biology, as well as discuss current and future utilization of these receptors for imaging and therapy in lung cancer.
SOMATOSTATIN RECEPTORS AND THEIR LIGANDS
Somatostatin receptors (SSTR) are members of the family of G protein coupled receptors (GPCRs) and are widely expressed in tissue throughout the body, including many tumors (3) .
There are five known subtypes of SSTRs (SSTR1-SSTR5) (Table 1) . They bind the hormone somatostatin, of which there are two biologically active forms, SST-14 and SST-28.
70 J Lung Cancer 2011;10(2):69-76 Somatostatin binds to all of the SSTRs without preference, but the result of somatostatin binding appears to be receptor specific as well as organ dependent, though there is some overlap between the different receptor subtypes. Somatostatin has several downstream effects, including influencing cellular secretion, motility, and even proliferation. It is a major endocrine "off switch" including control of hormone secretion and with significant antiproliverative properties (4-6). It has both autocrine and paracrine activity. SSTRs modulate several key enzymes involved in the cell cycle, including inhibition of adenylate cyclase, impairment of calcium influx, increasing p53 expression and Bax to initiate apoptosis, and also affecting ERK1/2 and AKT to decrease cell proliferation (5, 7) . For these reasons, not only do SSTRs play a major role in normal human biology, but also they are key players in cancer biology.
Somatostatin and its receptors are found throughout the body with resulting physiologic activity, but for this review, we will try to limit our focus to their role in lung cancer. The first synthetic analog for a SSTR was created against SSTR2 in the late 1970s (8) , and now SSTR2 analogs such as octreotide and lanreotide are used clinically in several types of endocrine and neuroendocrine cancers. The half-life of the endogenously produced hormone is less than 3 minutes (9), so the creation of these synthetic peptides with longer half-lives has allowed for advances in our understanding of SSTRs. The inhibitory effects of somatostatin analogs such as octreotide are Although all of the SSTRs have biologic importance and are expressed in lung cancers, SSTR2 is the most studied (partly because of the early creation of synthetic SSTR2 analogs), and therefore much of our discussion with regards to lung cancer will focus on it. 
SOMATOSTATIN SIGNALING SWITCHES OFF PROLIFERATION

TARGETING SSTR2 IN HUMAN STUDIES
SSTR2 is widely expressed in pulmonary neuroendocrine tumors, including typical carcinoids, atypical carcinoids, large cell neuroendocrine, and small cell lung cancer (18) (19) (20) .
Altogether, these tumor types make up approximately 25% of all lung cancers (21) . There are mixed reports of SSTR2 expression in non-neuroendocrine lung cancers, including adenocarcinoma and squamous cell carcinoma (18, 22) , with inconsistent and sometimes even lack of correlation between immunohistochemistry, PCR, and radiolabeled somatostatin analog uptake. 
PEPTIDE-RECEPTOR BASED RADIATION THERAPY
Researchers are beginning to exploit radiolabeled soma- 
